Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.50 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17069238 | 0.85 | SLC6A2 (0.51) | IDO1SLC6A2SLC6A4SLC6A3PDE3B | |
| SCHEMBL12844885 | 0.81 | PDE3B (0.45) | IDO1SLC6A2SLC6A4SLC6A3PDE3B | |
| SCHEMBL17914474 | 0.81 | PDE3B (0.45) | IDO1SLC6A2SLC6A4SLC6A3PDE3B | |
| SCHEMBL17069269 | 0.80 | PDE3B (0.47) | IDO1SLC6A2SLC6A4SLC6A3PDE3B | |
| SCHEMBL17069266 | 0.80 | POLQ (0.46) | IDO1SLC6A2SLC6A4SLC6A3PDE3B | |
| SCHEMBL488748 | 0.79 | IDO1 (0.59) | IDO1SLC6A2SLC6A4SLC6A3P2RX7 | |
| SCHEMBL29616489 | 0.79 | IDO1 (0.59) | IDO1SLC6A2SLC6A4SLC6A3P2RX7 | |
| SCHEMBL8417818 | 0.79 | IDO1 (0.59) | IDO1SLC6A2SLC6A4SLC6A3EPHX2 | |
| SCHEMBL1538597 | 0.78 | IDO1 (0.63) | IDO1SLC6A2SLC6A4SLC6A3P2RX7 | |
| SCHEMBL3904394 | 0.77 | PDE3B (0.42) | SLC6A2SLC6A4SLC6A3PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3784669-B1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMA (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-4174069-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Wuhan LL Science and Technology Development Co., Ltd. (CN) | 2023-05-03 | — | — | EP | disclosed |
| US-11332463-B2 | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | MERCK SHARP & DOHME CORP. (US) | 2022-05-17 | — | — | US | disclosed |
| US-20220047592-A1 | METHODS OF TREATING RESPIRATORY DISEASES USING C5a INHIBITORS | CHEMOCENTRYX, INC. | 2022-02-17 | — | — | US | disclosed |
| US-11242331-B2 | Analogs of yohimbine and uses thereof | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-02-08 | — | — | US | disclosed |
| WO-2022001767-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | 武汉朗来科技发展有限公司 | 2022-01-06 | — | — | WO | disclosed |
| US-11149002-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-11059826-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210106568-A1 | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | CHEMOCENTRYX, INC. | 2021-04-15 | — | — | US | disclosed |
| US-20210093618-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-04-01 | — | — | US | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-9694002-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9694002-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20170087136-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-20170087136-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-9546164-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20150252038-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2015-09-10 | — | — | US | disclosed |
| WO-2011132051-A2 | TRICYCLE COMPOUNDS AS PHOSPHODIESTERASE-10 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-10-27 | — | — | WO | disclosed |
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | METASTATIX, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | METASTATIX, INC. | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | IDO1 2995/4885SLC6A2 1205/4885SLC6A4 1914/4885 |
| US-11149002-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | IDO1 2995/4885SLC6A2 1205/4885SLC6A4 1914/4885 |
| US-11332463-B2 | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | CHRNA7, CHRNA5, CHRNA6 | IDO1 1335/4885SLC6A2 336/4885SLC6A4 1025/4885 |
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | MKI67, CCNI, CDKN1A | IDO1 522/4885SLC6A2 2909/4885SLC6A4 3384/4885 |
| US-11242331-B2 | Analogs of yohimbine and uses thereof | MAOA, MAOB, NPY5R | IDO1 44/4885SLC6A2 119/4885SLC6A4 238/4885 |
| US-11059826-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | IDO1 952/4885SLC6A2 3631/4885SLC6A4 3856/4885 |
| US-20210093618-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SULT2A1 | IDO1 2403/4885SLC6A2 1283/4885SLC6A4 1222/4885 |
| US-20150252038-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, RRM1 | IDO1 2828/4885SLC6A2 1679/4885SLC6A4 1432/4885 |
| US-20220047592-A1 | METHODS OF TREATING RESPIRATORY DISEASES USING C5a INHIBITORS | C3AR1, C5, C5AR1 | IDO1 371/4885SLC6A2 4023/4885SLC6A4 4061/4885 |
| US-20210106568-A1 | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | C5AR1, C5AR2, C3AR1 | IDO1 1142/4885SLC6A2 1891/4885SLC6A4 2100/4885 |
| US-20170087136-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | C1R, SRR, PNISR | IDO1 2555/4885SLC6A2 927/4885SLC6A4 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.